Drugs /
tasquinimod
Back to Drugs List
Overview
NCI Definition [1]:
A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
Clinical Trials
Tasquinimod has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tasquinimod, 1 is phase 1 (1 open).
Multiple myeloma is the most common disease being investigated in tasquinimod clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
